Project Grant HT94252310606

This Project Grant award, funded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development and clinical evaluation of next-generation CAR-NK cell therapies targeting CD5-positive T-cell malignancies. The $1,847,485 award to the University of Texas MD Anderson Cancer Center aims to advance a novel CAR-NK cell product, termed IC9/CAR5-28Z/IL-15 NK cells, that leverages key advantages of NK cells over traditional CAR-T cell therapies. The project seeks to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...

The National Cancer Institute (NCI) awarded a $402,600 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The primary goals of this 5-year project are to develop these CAR T-cell therapies and investigate the mechanism by which U5 snRNP is...

The National Cancer Institute (NCI) awarded a $1,125,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Kure Ai Inc. to develop an "Ultra-Fast Manufactured CAR-T Therapy" with improved efficacy and safety compared to current CAR-T cell therapies. The project aims to 1) validate an automated, closed-system manufacturing process for this rapid CAR-T product through a Phase 1b clinical trial, and 2) extend the safety and efficacy data in a defined...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting a Phase 2 multi-center clinical trial of a novel CD5 CAR T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma (R/R TCL). The $1,124,607 award, with a performance period of Jul 1, 2025 to Jun 30, 2027, aims to validate the safety and efficacy of this innovative cellular therapy that is engineered to selectively target...

The National Cancer Institute (NCI) awarded a $399,444 Project Grant to Cancure LLC (doing business as Canzx Biotherapeutics) under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The grant will fund a feasibility study of a novel agent that can stimulate NK (natural killer) and CD8 T cells to improve the efficacy of cell-based cancer therapies, particularly for solid tumors. The goal is to develop an agent that can induce polyfunctional heterogenic...

This $1,340,987 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel "CAR-Enhancer" platform to improve the effector function and persistence of CAR T-cells. The project's key objectives are to: 1) Optimize dosing and timing for CAR-Enhancer administration in a Phase I clinical trial, 2) Establish a scalable manufacturing process, and 3) Assess the...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will provide real-time information on the endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma (MM) undergoing bispecific T-cell engager antibody (BiTEA) treatment. The goal is to better understand T-cell engagement and trafficking...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $399,739 to Ship Of Theseus LLC to develop a novel chimeric antigen receptor (CAR) T-cell therapy platform for treating hematologic malignancies. The key products/services being delivered under this grant include: Preclinical development of a tandem CAR-T and hematopoietic stem cell (HSC) transplantation approach, which leverages CRISPR base-editing to engineer donor HSCs to evade...